Biotechnology cancer Cancer Discovery

University of Pennsylvania to join new collaboration to fight cancer with immunotherapies

The University of Pennsylvania has joined an unprecedented cancer research effort, the Parker Institute for Cancer Immunotherapy, which unites six of the nation's top medical schools and cancer centers around a shared aim of accelerating breakthrough immunotherapy research that will turn more cancers into a curable disease. The venture is backed by a $250 million gift from the Parker Foundation, making it the largest single contribution ever made to the
Biomarkers cancer Cancer Discovery

New Study Implicates Unusual Class of Circular RNAs in Cancer

Cancer cells are notorious for their genomes gone haywire, often yielding fusion proteins — mash-ups of two disparate genes that, once united, assume new and harmful capabilities. Exactly how such genome scrambling impacts RNA, particularly the vast and mysterious world of non-coding RNA, has been largely unexplored. Now, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) offers some early answers by studying an intriguing class of
Biotechnology cancer Clinical Trials Radiopharmaceuticals

FDA Greenlights Orphan Drug Status for Radioimmuneconjugate for Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic that conditions relapsed and refractory Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Iomab-B will soon begin a 150 patient, pivotal Phase 3 multicenter trial in relapsed and refractory AML patients over the age of 55. Iomab-B is a radioimmunoconjugate consisting
Biotechnology cancer Clinical Trials

Cancer Immunotherapies take Center Stage

[embed]https://vimeo.com/151833021[/embed] The newly created task force on cancer, in what Vice President Joe Biden has called a “moon shot” to cure the disease, is to put the US on a path to achieve in just five years research and treatment that otherwise might take a decades or more.  Although the memorandum does not commit the government to major new spending, the task force's role will be to focus on making
Biotechnology cancer Clinical Trials

Many Targeted Cancer Therapies Suppress T Cell Immune Responses

In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations. In clinical trials, a heavy emphasis on the effects of targeted therapies on tumor cells has been explored, but the effects they have on the immune system have not been thoroughly investigated. However,
cancer Clinical Trials

UGA Researchers Find Potential Treatment for Prostate Cancer

Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models of the disease. They published their findings recently in the journal Nanomedicine: Nanotechnology, Biology and Medicine. The treatment is designed to inhibit the activity of a protein called PAK-1, which contributes to the development of highly invasive prostate cancer cells. Aside from non-melanoma skin cancer, prostate cancer is